Suchergebnisse - "Heider, Michael"

PubPharm (18)

1

Stress response silencing by an E3 ligase mutated in neurodegeneration

enthalten in: Nature | 2024

von Haakonsen, D. | Heider, M. | Ingersoll, A. | +5

2

Assessing Model Requirements for Explainable AI : A Template and Exemplary Case Study

enthalten in: Artificial life | 2023

von Heider, M. | Stegherr, H. | Nordsieck, R. | +1

3

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

enthalten in: Blood advances | 2023

von Heynen, G. | Baumgartner, F. | Heider, M. | +22

4

The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myeloma

enthalten in: The EMBO journal | 2022

von Paulmann, C. | Spallek, R. | Karpiuk, O. | +15

5

Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma

enthalten in: EJNMMI research | 2022

von Morath, V. | Heider, M. | Mittelhäuser, M. | +6

6

Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma

enthalten in: EJNMMI Research | 2022

von Morath, V. | Heider, M. | Mittelhäuser, M. | +6

7

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma

enthalten in: Blood advances | 2022

von Stroh, J. | Seckinger, A. | Heider, M. | +13

8

The OTUD6B‐LIN28B‐MYC axis determines the proliferative state in multiple myeloma

enthalten in: The EMBO Journal | 2022

von Paulmann, C. | Spallek, R. | Karpiuk, O. | +15

9

Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma

enthalten in: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis | 2021

von Heider, M. | Grass, S. | Dill, V. | +6

10

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma

enthalten in: Molecular cell | 2021

von Heider, M. | Eichner, R. | Stroh, J. | +19